SPECIALTY
Infectious Disease

STAGE
Early stage

POSITION
Co-Investor

BOARD
BOD Observer until August 2018

EXIT
Acquired by Otsuka Pharmaceutical Co., Ltd. in August 2018

Visterra was a clinical-stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Visterra’s Hierotope platform, comprised of novel computational and experimental technologies, enables the design and engineering of precision antibody-based therapies that specifically bind to, and modulate, disease targets that are not adequately addressed by current technologies in antibody therapeutics. Visterra also used its novel Hierotope™ platform to identify unique disease targets and to design and engineer innovative antibody-based therapies intended to be effective as a single-dose administration. Visterra’s technology enabled the design and engineering of product candidates which target a specific region of an antigen, or Hierotope. Visterra’s pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases with its lead product candidate, VIS410, was a human monoclonal antibody being developed for the treatment of hospitalized patients with influenza A, regardless of viral strain. The company was acquired by Otsuka Pharmaceutical Co., Ltd. in August 2018.